Allogene Therapeutics company information, Employees & Contact Information

Allogene Therapeutics Announces Participation in March Investor Conference Allogene

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO Allogene

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer Allogene

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman Allogene

Leading AlloCAR T Developer Allogene Therapeutics to Share Updates at Citi Biopharma Summit Stock Titan

Allogene Therapeutics Schedules Conference Call and Webcast to Discuss Q2 2025 Financial Results on August 13 Quiver Quantitative

Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events Stock Titan

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS Allogene

Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products Allogene

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma Allogene

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer Allogene

Allogene Therapeutics Announces Departure of Chief Financial Officer Allogene

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform Allogene

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting Allogene

Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development Allogene

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Allogene

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma Allogene

Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report Allogene

Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting Allogene

Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting Allogene

Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma Allogene

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel Yahoo Finance

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma GlobeNewswire

Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma Allogene

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update GlobeNewswire

“Off-the-shelf” CAR T – New frontiers in autoimmune disease statnews.com

Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting Allogene

Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia Allogene

Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies Allogene

Allogene Therapeutics Announces Publication of Durable GlobeNewswire

Allogene Granted Three U.S. FDA Fast Track Designations GlobeNewswire

Allogene Therapeutics Pivots ALPHA3 Trial Strategy: Adopts Standard FC Protocol After Safety Review Stock Titan

Allogene Therapeutics Announces Exclusive Collaboration and GlobeNewswire

Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer Business Wire